ICD-10 R73.09 is officially defined as "Other abnormal glucose." code R73.09 is referenced in 5 tracked payer policy changes from Independence Blue Cross, Horizon BCBS NJ, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R73.09 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Independence Blue Cross expanded coverage for Teplizumab-mzwv (Tzield) to include pediatric patients aged 1 to <8 years with stage 2 type 1 diabetes, while maintaining non-coverage for patients aged 8-17 with stage 3 T1D (classified as experimental/investigational). Six ICD-10 diagnosis codes were removed from the policy. Billing teams must update systems to reflect the new pediatric age coverage expansion effective December 7, 2026.
This is a new Medicare Part D Star Ratings measure (SUPD) effective for 2026 that evaluates whether patients ages 40-75 with diabetes on antidiabetic medications are also receiving statin therapy. Billing teams must ensure proper documentation and ICD-10 coding of exclusionary diagnoses to accurately track eligible patients and avoid measure performance penalties. Claims must include appropriate exclusion codes when patients have contraindications to statin therapy.
Capital Blue Cross updated Medicare Part D Star measures for 2026, adding new exclusions for Statin Use in Persons with Diabetes (SUPD) that recognize PCSK9 inhibitors and bempedoic acid as alternatives for patients who cannot tolerate statins. Providers must submit specific ICD-10-CM codes annually during in-person or audio/video visits to qualify patients for exclusions from the SUPD measure.
CPT 90785 (interactive complexity) may be billed only as an add-on code that accompanies an eligible primary psychiatric service, and only when its specific criteria and requirements are met. Medical records must clearly support CPT 90785 by describing specific communication challenges, challenges affecting clinical interaction, the interactive methods used, and why standard communication approaches were insufficient, and claims submitted without adequate documentation may be subject to audit or review with payment adjusted if billing requirements are not met. Nail pathogen panel claims should be supported by clear clinical indication and medical necessity, prior testing and treatment history, a valid signed provider order specifying test type, and accurate diagnosis coding, and the Presbyterian Program Integrity Department performs random claims validation audits.
This is a reissue with no substantive changes to the Tzield (teplizumab-mzwv) coverage policy. The policy was previously updated on 11/18/2024 to remove medical necessity criteria based on family history of type 1 diabetes; this 05/28/2025 reissue confirms those changes under the annual review process. Coverage remains limited to stage 2 type 1 diabetes in patients 8+ years old who meet specific autoantibody and glucose tolerance criteria, prescribed by an endocrinologist, with one lifetime treatment course of 14 doses.
Watch R73.09
Get one email when a payer policy names R73.09, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.